Abstract 93P
Background
Endometrial carcinomas (EC) are the most common gynecological cancer in the developed world. The original histopathology-based classification has been supplemented in the recent years by a molecular classification, based on the analysis of POLE mutation, microsatellite instability (MSI) and copy number variation. These markers have been used to develop prognostic risk groups with specific treatment options. Hence, the molecular stratification has been recommended internationally by different organizations and associations (e.g., ESMO, ESGO), allowing individualized treatment stratifications. Historically, these markers have been analyzed by various methods such as immunohistochemistry (IHC), Sanger sequencing and PCR-based fragment analysis. But the lack of single streamlined workflow has hampered the widespread adoption.
Methods
We developed three assays for discrimination of EC into ultramutated (POLE), hypermutated (MSI) and copy number high (CN high) phenotypes. CN high tumors are stratified based on molecular level with two newly identified biomarkers. We pre-characterized a patient cohort compromising of 41 samples, using IHC (MLH1, MSH2, MSH6, PMS2 and the surrogate marker TP53). Using our proprietary molecular analysis platform MODAPLEX, that unifies PCR and capillary gel electrophoresis, we analyzed this cohort with the three assays with a 4-hour turn-around time. The concordance was determined by calculation of the sensitivity.
Results
The concordance analysis of our MODAPLEX assays revealed a sensitivity of 0.923 (95% CI [0.781, 1.066]) for MSI compared to the IHC results and 0.833 (95% CI [0.622, 1.044]) for CN high compared to p53-IHC, respectively. We verified 100% of the mutations identified with the MODAPLEX POLE/POLD1 assay.
Conclusions
Overall, this study demonstrates a multi-gene/multi-marker testing workflow with complete molecular stratification for EC into a single streamlined, time- and cost-effective run. This approach will allow timely access to molecular-guided therapy for individual patients by enabling same day results, with a relative ease of implementation and fully integrated data analysis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Biotype GmbH, Dresden, Germany.
Funding
Biotype GmbH, Dresden, Germany.
Disclosure
S. Walz, C. Schanzenbach, A. Aich, R. Weißbach, R. Braun, A. Hennig, J. Schoebel, S. Hofmann: Financial Interests, Institutional, Full or part-time Employment: Biotype GmbH.
Resources from the same session
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract
63P - The impact of disruption of melatonin secretion on the structural-functional changes of the microbiome and the role of the melatonin-microbiome axis in the initiation of carcinogenesis
Presenter: Alexandre Tavartkiladze
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Acidosis induces ferroptosis of breast cancer via ZFAND5/SLC3A2 axis with the synergistic effect of metformin and facilitates M1 macrophage polarization
Presenter: Hanchu Xiong
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Transmembrane distribution of phosphatidylethanolamine in plasma membrane of ovarian cancer cells under conditions mimicking tumor microenvironment
Presenter: Darya Savenkova
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma
Presenter: Liam Wilson
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma
Presenter: Aline Atallah
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Integrated OMIC analysis reveals arginine and proline metabolism plays critical role in hypoxia-induced oral squamous cell carcinoma
Presenter: Avinash Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Individualising methotrexate dose based on MTHFR gene polymorphisms in acute lymphoblastic leukemia
Presenter: Meher Konatam
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer
Presenter: Sandro Surmava
Session: Cocktail & Poster Display session
Resources:
Abstract